Skip to content

An exploratory randomized controlled trial of electroacupuncture combined with repetitive transcranial magnetic stimulation for the treatment of Alzheimer's disease

An exploratory randomized controlled trial of electroacupuncture combined with repetitive transcranial magnetic stimulation for the treatment of Alzheimer's disease

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400087379
Enrollment
Unknown
Registered
2024-07-26
Start date
2024-07-29
Completion date
Unknown
Last updated
2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease

Interventions

Electroacupuncture group:Electroacupuncture
Electroacupuncture+Repetitive transcranial magnetic stimulation group:Electroacupuncture+Repetitive transcranial magnetic stimulation

Sponsors

Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Comply with the NIA-AA standard and the most likely AD standard; (2) 50 years old= age = 85 years old; (3) 0.5 points= clinical dementia rating score =2 points; (4) Sign the informed consent form and voluntarily participate in this trial; If the subject has the ability to make a decision, he or she will sign the informed consent form; If the patient's cognitive level is low and he or she is unable to sign the informed consent, the legal guardian will sign it on his/her behalf.

Exclusion criteria

Exclusion criteria: (1) Accompanied by other neurological diseases or non-neurological diseases that can cause cognitive dysfunction or progressive memory impairment; (2) There are contraindications to acupuncture treatment, such as bleeding tendency at acupuncture points or allergy to metals; (3) Implantation of pacemakers, cochlear implants and defibrillators, etc.; (4) Severe magnetic allergic reaction; (5) Craniotomy or history of seizures; (6) there were no relatively fixed caregivers during the 16-week study period; (7) Participating in other clinical trials at the time of enrollment.

Design outcomes

Primary

MeasureTime frame
Alzheimer disease assessment scale cognition, ADAS-Cog;

Secondary

MeasureTime frame
Neuropsychiatric Inventory, NPI;Neuropsychiatric Inventory, NPI;Pittsburgh sleep quality index, PSQI;Clinician Interview–Based Impression of Change scale, CIBIC;

Countries

China

Contacts

Public ContactBaohui Jia

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

myrroossee@aliyun.com+86 135 2009 0050

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026